Antibe Therapeutics (STU:4B70) OCF Margin %: 0.00% (As of Dec. 2023)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics OCF Margin %?

Antibe Therapeutics STU:4B70 10 OCF Margin % is 0.00% as of Dec. 2023. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Antibe Therapeutics's Cash Flow from Operations for the three months ended in Dec. 2023 was €-2.63 Mil. Antibe Therapeutics's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Antibe Therapeutics's OCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Antibe Therapeutics's current OCF Yield % is 0.00%.

The historical rank and industry rank for Antibe Therapeutics's OCF Margin % or its related term are showing as below:


STU:4B70's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Antibe Therapeutics OCF Margin % Related Terms

Antibe Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics OCF Margin % Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.98 -117.41 0.00 0.00 0.00

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Antibe Therapeutics's OCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-11.13/0
= %

Antibe Therapeutics's OCF Margin for the quarter that ended in Dec. 2023 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.628/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Antibe Therapeutics (STU:4B70) has a OCF Margin % of 0.00% as of Dec. 2023. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' OCF Margin % too high?
Antibe Therapeutics' current OCF Margin % is 0.00%. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' OCF Margin % compare to VRTX and REGN?
Antibe Therapeutics' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Antibe Therapeutics and its competitors. Antibe Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current OCF Margin % is 0.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price